Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Common Equity (2022 - 2025)

Axsome Therapeutics' Common Equity history spans 4 years, with the latest figure at $88.3 million for Q4 2025.

  • For Q4 2025, Common Equity rose 54.86% year-over-year to $88.3 million; the TTM value through Dec 2025 reached $88.3 million, up 54.86%, while the annual FY2025 figure was $88.3 million, 54.86% up from the prior year.
  • Common Equity for Q4 2025 was $88.3 million at Axsome Therapeutics, up from $73.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $278.8 million in Q2 2023 and bottomed at $14.7 million in Q1 2022.
  • The 4-year median for Common Equity is $97.9 million (2024), against an average of $114.6 million.
  • The largest annual shift saw Common Equity surged 1734.36% in 2023 before it tumbled 70.15% in 2024.
  • A 4-year view of Common Equity shows it stood at $109.6 million in 2022, then skyrocketed by 74.32% to $191.0 million in 2023, then crashed by 70.15% to $57.0 million in 2024, then skyrocketed by 54.86% to $88.3 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Common Equity are $88.3 million (Q4 2025), $73.7 million (Q3 2025), and $73.1 million (Q2 2025).